CN101857642A - Polysaccharide derivative and vanadium complex application thereof - Google Patents
Polysaccharide derivative and vanadium complex application thereof Download PDFInfo
- Publication number
- CN101857642A CN101857642A CN200910020508A CN200910020508A CN101857642A CN 101857642 A CN101857642 A CN 101857642A CN 200910020508 A CN200910020508 A CN 200910020508A CN 200910020508 A CN200910020508 A CN 200910020508A CN 101857642 A CN101857642 A CN 101857642A
- Authority
- CN
- China
- Prior art keywords
- vanadium
- polysaccharide
- polysaccharide derivative
- polysaccharide derivates
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention discloses a preparation method of a polysaccharide derivative and vanadium complex, which comprises the following steps of: firstly, reacting NaOH-alkalifying polysaccharide with chloroacetic acid for 3-4 hours at the temperature of 40-80 DEG C to synthesize the polysaccharide derivative; then reacting the polysaccharide derivative with a vanadium solution for 12-24 hours at the room temperature to obtain the vanadium complex of the polysaccharide derivative. The polysaccharide derivative and vanadium complex is applied to medicines for treating diabetes mellitus. In the invention, the polysaccharide derivative is adopted as raw material and reacts with VOSO4 in an aqueous medium under the neutral condition to obtain the polysaccharide derivative and vanadium complex through filtration, drying and crushing. In the invention, the complex preparation is completely carried out at the room temperature, has simple process and is easy to realize industrial production.
Description
Technical field
The invention belongs to biomacromolecule metal complex field, is the complex compound of vanadium and polysaccharide derivates and the application in hypoglycemic drug thereof specifically.
Background technology
Vanadium through the research in century more than one, has been confirmed as the essential trace element of humans and animals in phase late 1970s since 1830 are found from iron ore by Sweden chemist Sefstrom.Find that in the diabetes animal model treatment vanadium has the effect of lowering blood glucose.Vanadium can be simulated the effect of Regular Insulin---suppress K
+-Na
+The reaction of the dephosphorylation of-ATP enzyme, thus the inside and outside ionic running balance of cell kept, activate glycometabolic main enzyme system, suppress the synthetic of steatolysis and liver cholesterol and phosphatide, increase stream in the calcium, promote the running and the oxidation of glucose, thus lowering blood glucose.No matter be I type (insulin-dependent) or II type (non-insulin-depending type) diabetes, all can impel blood sugar recovery to normal level with the vanadium compound treatment, strengthen the susceptibility of tissue to Regular Insulin, alleviate a series of complication.The preparation of relevant vanadium-containing compound, character and the report at aspects such as absorption by human body, distribution, removings mostly are mineral compound, have deficiencies such as absorption difference, toxicity be big.
The active group that not modified polysaccharide contains is less, the bonding action that forms with vanadium ion just relative a little less than, the metal content in the complex compound of formation is relatively low, reaches same curative effect required dosage and increases, bioavailability reduces, and the toxicity of organism is strengthened greatly.
Summary of the invention
Technical problem to be solved by this invention provides that a kind of toxicity is little, the vanadium complexes of the polysaccharide derivates of oral easy absorption.After polysaccharide is modified through carboxymethylation, because carboxymethyl has stronger complex ability with the vanadyl ion, the vanadyl complex of formation polysaccharide derivates, and make that the content of vanadium ion increases in the complex compound.
In order to address the above problem, the present invention specifically adopts following scheme:
The vanadium complexes of polysaccharide derivates, polysaccharide that at first NaOH has been alkalized and Monochloro Acetic Acid are at 40-80 ℃ of reaction 3-4 hour down, synthetic polysaccharide derivates; Then above-mentioned polysaccharide derivates and vanadium solution were at room temperature reacted 12-24 hour, obtain the vanadium complexes of polysaccharide derivates.
Polysaccharide comprises chitosan, carrageenin, synanthrin etc.;
The mass ratio of polysaccharide, NaOH and Monochloro Acetic Acid is 1: 1.2-1.5: 1.2-2;
The time of NaOH alkalization polysaccharide is 0.5-1.5h;
The mass ratio of polysaccharide derivates and vanadium ion is 100: 0.1-5;
Vanadium solution is VOSO
4The aqueous solution;
The temperature of reaction of polysaccharide and Monochloro Acetic Acid is 60 ℃.
The application of the vanadium complexes of this polysaccharide derivates in the treatment hypoglycemic drug.
Compared with prior art, the present invention has following advantage:
1, the present invention has the advantage of following three aspects: one, polysaccharide derivates itself has multiple pharmacological effect such as antitumor, anti-various cardiovascular diseasess, antiviral, anti-oxidant, hypoglycemic and strengthening immunity; Two, polysaccharide is modified through carboxymethylation, and at first, carboxymethylation strengthens the water-soluble of polysaccharide greatly, is easy to absorption and the utilization of organism; Secondly, the coordination of carboxymethylation polysaccharide and vanadium ion strengthens greatly, the content of the vanadium in the complex compound is raise, can give full play to the physiologically active of micro-vanadium and polysaccharide derivates, make both effect coordinate mutually and strengthen, improve vanadium utilizability in vivo, reach same curative effect required dosage and reduce, greatly reduce toxicity; Three, inorganic vanadium is converted into the organic vanadium of polysaccharide derivates as part, polysaccharide derivates itself is nontoxic, but also have certain prevention and reduce the ability of the toxic side effect of vanadium, the coordination environment that provides leaves certain room and becomes key position with weak when forming title complex, ligand exchange can take place, be convenient to combining of complex compound and substrate, improved the mode of vanadium absorption in vivo, distribution, metabolism and removing simultaneously.
2, the existing report of the complexing of transition metal ion and sugar, but the complexing of general Study transition metal and monose or disaccharides, and reaction medium is a methyl alcohol.It is raw material that the present invention adopts the derivative of polysaccharide, in aqueous medium, and the following and VOSO of neutrallty condition
4Reaction through filtration, dry, pulverizing, obtains the complex compound of vanadium and polysaccharide derivates.Among the present invention, the preparation of complex compound is carried out fully at ambient temperature, and technology is simple, is easy to realize suitability for industrialized production.
Description of drawings
Fig. 1 is the infrared spectrogram of chitosan;
Fig. 2 is the infrared spectrogram of cm-chitosan;
Fig. 3 is the infrared spectrogram of cm-chitosan vanadyl complex;
Fig. 4 is the infrared spectrogram of carrageenin polysaccharide;
Fig. 5 is the infrared spectrogram of carboxymethyl carrageenin;
Fig. 6 is the infrared spectrogram of carboxymethyl carrageenin vanadyl complex.
Embodiment
The present invention will be described in detail below in conjunction with embodiment:
Embodiment 1: with 50.0g chitosan swelling 20min in the 450ml Virahol, drip massfraction and be 50% NaOH solution 120.0g and alkalize, alkalize after 1 hour, the 60.0g Monochloro Acetic Acid is dissolved in is added drop-wise in the 75ml Virahol in the above-mentioned reaction solution, system is warmed up to 60 ℃ then, isothermal reaction 3.5 hours, after reaction finishes, treat that temperature drops to room temperature after, regulating pH value is neutrality, add 3 times of volume of ethanol sedimentations, filter washing, drying, pulverize, obtain the carboxymethylation chitosan; The 5.0g cm-chitosan is dissolved in the 130ml deionized water, it is neutral regulating the pH value, drip the 0.1609gVOSO4 solid simultaneously and be made into the aqueous solution of 20ml, reacted 12 hours, and added 4 times of volume of ethanol sedimentations, filter, with filtration cakes torrefaction, pulverize, promptly get the complex compound of lurid vanadium and cm-chitosan, the content of vanadium is 0.75% in the complex compound.
Fig. 1 is the characteristic infrared (cm of chitosan
-1): 3379.64,2879.2,1644.98,1421.28,1320.04,1083.80; Fig. 2 is the characteristic infrared (cm of cm-chitosan
-1): 3408.57,2918.74,1603.52,1421.28,1321.00,1066.44; Fig. 3 is the characteristic infrared (cm of cm-chitosan vanadyl complex
-1): 3371.92,2918.74,1599.66,1416.46,1324.86,1070.30.Fig. 2 compared to Figure 1, at 1603.52cm
-1The place new absorption peak, 1603.52cm have appearred
-1Corresponding is the stretching vibration peak of carboxyl in the cm-chitosan, has proved the formation of target compound cm-chitosan.Fig. 3 compares with Fig. 2, and certain displacement has all taken place some characteristic peaks, and peak width and absorption intensity weaken, and illustrates that these groups have all participated in and the complexing of vanadyl ionic.Illustrate that vanadium oxonium ion and cm-chitosan combine with the form of chemical bond and formed the complex compound with certain constitutional features.
Embodiment 2: with 50.0g carrageenin swelling 25min in the 750ml Virahol, drip massfraction and be 50% NaOH solution 120.0g and alkalize, alkalized 1.5 hours, the 60.0g Monochloro Acetic Acid is dissolved in is added drop-wise in the 75ml Virahol in the above-mentioned reaction solution, system is warmed up to 60 ℃ then, isothermal reaction 4 hours, after reaction finishes, treat that temperature drops to room temperature after, regulating pH value is neutrality, add 3 times of volume of ethanol sedimentations, filter washing, drying, pulverize, obtain the carboxymethylation carrageenin; 30.0g carboxymethyl carrageenin is dissolved in the 600.0ml deionized water, and it is neutral regulating the pH value, drips 0.966gVOSO simultaneously
4Solid is made into the aqueous solution of 100ml, reacts 24 hours, adds 4 times of volume of ethanol sedimentations, filters, and with filtration cakes torrefaction, pulverizes, and promptly gets the complex compound of milky vanadium and carboxymethyl carrageenin, and the content of vanadium is 0.43% in the complex compound.
Fig. 4 has shown the characteristic absorbance of carrageenin, 3409.53cm fully
-1The absorption peak of position is the stretching vibration characteristic peak of hydroxyl, 2962.13cm
-1The absorption peak of position is a C-H stretching vibration absorption peak, 1234.22cm
-1The absorption peak of position is the asymmetric stretching vibration peak of sulfur-to-oxygen double bond in the sulfate, 926.63cm
-1The absorption peak of position is the charateristic avsorption band of 3,6 inner ether semi-lactosis, 848.53cm
-1The absorption peak prompting sulfate of position is connected the C-4 position of galactosyl.
Fig. 5 compares with Fig. 4, at 1610.27cm
-1The place new absorption peak, 1610.27cm have appearred
-1Corresponding is the stretching vibration peak of carboxyl in the carboxymethyl carrageenin, has proved the formation of target compound carboxymethyl carrageenin.
Fig. 6 compares with Fig. 5, can find, is positioned at 1610.27cm
-1The absorption peak of carboxymethyl carrageenin vanadyl complex carboxyl obviously weaken, illustrate that complex reaction has taken place for carboxyl and vanadyl ion; Be positioned at 3443.28cm
-1The absorption peak of carboxymethyl carrageenin vanadyl complex hydroxyl obvious displacement taking place and absorbs obviously weakens, illustrated that complex reaction has taken place for part of hydroxyl and vanadyl ion; Be positioned at 1255.43cm
-1The vibration peak and the 927cm of sulfur-to-oxygen double bond
-1The charateristic avsorption band of 3,6 inner ether semi-lactosis compare with the carboxymethyl carrageenin, absorption intensity weakens, and illustrates that the Sauerstoffatom of two keys of S=O and ehter bond has also participated in and the complexing of vanadyl ionic.Illustrate that vanadium oxonium ion and carboxymethyl carrageenin combine with the form of chemical bond and formed the carboxymethyl carrageenin vanadyl complex with certain constitutional features.
Embodiment 3: with 50.0g synanthrin swelling 20min in the 400ml Virahol, drip massfraction and be 50% NaOH solution 120.0g and alkalize alkalization 45min, the 60.0g Monochloro Acetic Acid is dissolved in is added drop-wise in the 75ml Virahol in the above-mentioned reaction solution, system is warmed up to 60 ℃ then, isothermal reaction 4 hours, after reaction finishes, treat that temperature drops to room temperature after, regulating pH value is neutrality, add 3 times of volume of ethanol sedimentations, filter washing, drying, pulverize, obtain the carboxymethylation synanthrin; The 5.0g carboxymethyl inulin is dissolved in the 100.0ml deionized water, and it is neutral regulating the pH value, drips 0.1609gVOSO simultaneously
4Solid is made into the aqueous solution of 20ml, reacts 15 hours, adds 4 times of volume of ethanol sedimentations, filters, and with filtration cakes torrefaction, pulverizes, and promptly gets the white vanadium and the complex compound of carboxymethyl inulin, and the content of vanadium is 0.35% in the complex compound.
Embodiment 4: hypoglycemic activity experiment, and select for use the vanadium complexes of cm-chitosan and the vanadium complexes of carboxymethyl carrageenin to carry out hypoglycemic experiment, as a sample, mass concentration is 5% with the vanadium complexes of cm-chitosan; As No. two samples, mass concentration is 10% with the vanadium complexes of carboxymethyl carrageenin.At first, make the diabetes model of mouse, select the Kunming kind healthy male mice of body weight 20-24g for use, adapt to experimental situation after 5 days, fasting 20h, with 160mg/kg body weight dosage abdominal injection, fasting is 6 hours after 5 days with freshly prepared tetraoxypyrimidine, measure fasting plasma glucose, with 10mmol/L＜blood sugar＜25mmol/L as diabetic mice.
In the hypoglycemic experiment of diabetic mice, selecting the Kunming kind healthy male mice random packet of body weight 20-26g for use is the normal control group, it is model control group, glyburide (Glyburide) control group, low dose group, middle dosage group, high dose group that diabetic mice is divided into 5 groups at random by blood glucose value level disease, 10 every group.Normal control group and the isopyknic tap water of high sugared model control group gastric infusion, glyburide control group, low dose group, middle dosage group, the isopyknic finite concentration sample of high dose group gastric infusion, administration time is 21d, carries out fasting plasma glucose when experiment finishes and measures.
Table 1 is the influence to hyperglycemia model mouse body weight of sample
Table 2 is the influence to the mouse fasting plasma glucose of sample
Annotate: as shown in Table 2, compare P＞0.05, * P＜0.05, * * P＜0.01 with normal control;
Compare P＞0.05 with model, #P＜0.05, ##P＜0.01;
Compare P＞0.05 with the Glyburide control group; P＜0.05 ， ﹠amp; ﹠amp; P＜0.01
Can draw from the data of table 1, No. one sample does not have influence substantially to hyperglycemia model mouse body weight; From the data of table 2 as can be known, a sample basic, normal, high dosage group in the hypoglycemic experiment of diabetic mice therapeutic all has remarkable blood sugar reducing function (P＜0.05) to fasting plasma glucose, and middle dosage group particularly significantly (P＜0.01) does not have notable difference (P＞0.05) with each dosage group blood sugar reducing function of Glyburide group comparison.
Table 3 is the influence to hyperglycemia model mouse body weight of No. two samples
Table 4 is the influence to the mouse fasting plasma glucose of No. two samples
Annotate: as shown in Table 4, compare P＞0.05, * P＜0.05, * * P＜0.01 with normal control
Compare P＞0.05 with model, #P＜0.05, ##P＜0.01
Compare P＞0.05 with the Glyburide control group; P＜0.05 ， ﹠amp; ﹠amp; P＜0.01
No. two samples do not have influence substantially to hyperglycemia model mouse body weight as can be seen from Table 3; As known from Table 4, No. two samples are in the hypoglycemic experiment of diabetic mice therapeutic, and basic, normal, high dosage group all has remarkable blood sugar reducing function (P＜0.05) to fasting plasma glucose and diabetic mice sugar dosis tolerata, and high dose group particularly significantly (P＜0.01).With Glyburide group comparison high dose group blood sugar reducing function notable difference (P＜0.05) is arranged, other dosage group blood sugar reducing functions do not have notable difference (P＞0.05).
Experimental result shows: the vanadium complexes of the vanadium complexes of cm-chitosan and carboxymethyl carrageenin all has significant blood sugar reducing function to fasting plasma glucose and the anti-sugar amount of diabetic mice in the hypoglycemic experiment of diabetic mice.
Claims (8)
1. the vanadium complexes of a polysaccharide derivates is characterized in that: polysaccharide that at first NaOH has been alkalized and Monochloro Acetic Acid are at 40-80 ℃ of reaction 3-4 hour down, synthetic polysaccharide derivates; Then above-mentioned polysaccharide derivates and vanadium solution were at room temperature reacted 12-24 hour, obtain the vanadium complexes of polysaccharide derivates.
2. the vanadium complexes of polysaccharide derivates according to claim 1, it is characterized in that: polysaccharide comprises chitosan, carrageenin or synanthrin.
3. the vanadium complexes of polysaccharide derivates according to claim 1, it is characterized in that: the mass ratio of polysaccharide, NaOH and Monochloro Acetic Acid is 1: 1.2-1.5: 1.2-2.
4. according to the vanadium complexes of claim 1,2 or 3 described polysaccharide derivates, it is characterized in that: the time of NaOH alkalization polysaccharide is 0.5-1.5h.
5. the vanadium complexes of polysaccharide derivates according to claim 1 and 2, it is characterized in that: the mass ratio of polysaccharide derivates and vanadium is 100: 0.1-5.
6. the vanadium complexes of polysaccharide derivates according to claim 1, it is characterized in that: vanadium solution is the aqueous solution of VOSO4.
7. the vanadium complexes of polysaccharide derivates according to claim 1, it is characterized in that: the temperature of reaction of polysaccharide and Monochloro Acetic Acid is 60 ℃.
8. the application of the vanadium complexes of polysaccharide derivates as claimed in claim 1 in the treatment hypoglycemic drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910020508A CN101857642B (en) | 2009-04-10 | 2009-04-10 | Polysaccharide derivative and vanadium complex application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910020508A CN101857642B (en) | 2009-04-10 | 2009-04-10 | Polysaccharide derivative and vanadium complex application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101857642A true CN101857642A (en) | 2010-10-13 |
| CN101857642B CN101857642B (en) | 2012-08-29 |
Family
ID=42943826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910020508A Expired - Fee Related CN101857642B (en) | 2009-04-10 | 2009-04-10 | Polysaccharide derivative and vanadium complex application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101857642B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104447852A (en) * | 2014-11-17 | 2015-03-25 | 云南大学 | Novel schiff base vanadium oxide compound as well as preparation method and application thereof |
| CN109206529A (en) * | 2018-08-20 | 2019-01-15 | 福建农林大学 | A kind of processing method of high water holding carragheen |
| CN109734761A (en) * | 2019-02-28 | 2019-05-10 | 福建农林大学 | A kind of preparation method and applications of Enteromorpha fucose complex compound |
| CN109851683A (en) * | 2018-12-12 | 2019-06-07 | 兰州大学 | A kind of metal complex, a kind of preparation method and application of metal complex |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1207300C (en) * | 2003-09-01 | 2005-06-22 | 中国海洋大学 | Combined holoside as well as preparation method and application |
-
2009
- 2009-04-10 CN CN200910020508A patent/CN101857642B/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104447852A (en) * | 2014-11-17 | 2015-03-25 | 云南大学 | Novel schiff base vanadium oxide compound as well as preparation method and application thereof |
| CN104447852B (en) * | 2014-11-17 | 2017-02-22 | 云南大学 | Schiff base vanadium oxide compound as well as preparation method and application thereof |
| CN109206529A (en) * | 2018-08-20 | 2019-01-15 | 福建农林大学 | A kind of processing method of high water holding carragheen |
| CN109851683A (en) * | 2018-12-12 | 2019-06-07 | 兰州大学 | A kind of metal complex, a kind of preparation method and application of metal complex |
| CN109734761A (en) * | 2019-02-28 | 2019-05-10 | 福建农林大学 | A kind of preparation method and applications of Enteromorpha fucose complex compound |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101857642B (en) | 2012-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100545164C (en) | The preparation technology of disodium cantharidinate | |
| CN101693730B (en) | Mangiferin and preparation method and application thereof | |
| CN1762378A (en) | Indian bread polysaccharide formulation and its preparation method | |
| CN101560267B (en) | Preparation method of polysaccharide selenite | |
| CN101857642B (en) | Polysaccharide derivative and vanadium complex application thereof | |
| CN103040730A (en) | Iron sucrose injection and preparation method thereof | |
| CN103435715A (en) | Preparation method and application of vanadium complexes of oligosaccharides and derivatives thereof | |
| CN101485666B (en) | Application of Gamabufotalin and salt thereof in preparing medicament for treating gynaecologic tumor | |
| CN104587486A (en) | Chitosan-platinum (IV) prodrug conjugate and preparation method thereof | |
| CN109734761A (en) | A kind of preparation method and applications of Enteromorpha fucose complex compound | |
| CN101691344B (en) | Metformin acidic double salt compound and preparation method | |
| CN101224246B (en) | Preparing method of loquat leaf total triterpenic acid and antidiabetic use thereof | |
| CN103059154B (en) | Fungal glucan oligomer chrome complex and preparation method thereof | |
| CN111743924A (en) | Marine plant extract for treating diabetes, composition and application | |
| CN104861016A (en) | Glycyrrhizic acid metal complex preparation method | |
| CN101328224B (en) | Fructus choerospondiatis polysaccharide metal complexe and preparation thereof | |
| CN102093323B (en) | Quercetin preparation method | |
| CN104628765B (en) | A kind of preparation method with the double rheum emodin vanadyl coordination compound of hypoglycemic activity | |
| JP2004010605A (en) | Antitumor agent given by using mixture of deacetylated and deoxygenated mushrooms, fermented ganoderma spawn, and other mixture, and health food product, and feed additive containing the agent | |
| CN101633661B (en) | Process for preparing sodium cantharidinate | |
| CN102885847A (en) | Novel uses of camellia oleifera cake polysaccharide | |
| CN101654487B (en) | Preparation method for vanadium polysaccharide complex and application thereof | |
| CN102688248A (en) | Use of bufadienolide compound in preparing medicines for treating oral mucosal malignant tumors | |
| CN103804392B (en) | Two kinds of terphenyls dioxazines derivative and application thereof | |
| CN105455120A (en) | Golden camellia tea assisted blood sugar lowering capsule |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: YANTAI INSTITUTE OF COASTAL ZONE RESEARCH, CHINESE Free format text: FORMER OWNER: YANTAI HAIANDAI SUSTAINABLE DEVELOPMENT INSTITUTE Effective date: 20120821 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20120821 Address after: Chunhui road Laishan District 264003 Shandong city of Yantai province No. 17 Patentee after: Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences Address before: Chunhui road Laishan District 264003 Shandong city of Yantai province No. 17 Patentee before: Yantai Haiandai Sustainable Development Institute |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120829 Termination date: 20170410 |